Tuberculosis Diagnostics: State of the Art and Future Directions.
暂无分享,去创建一个
[1] M. Pai,et al. Mind the gap: Time to address implementation gaps in tuberculosis diagnosis and treatment , 2016, Journal of clinical tuberculosis and other mycobacterial diseases.
[2] S Niemann,et al. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement. , 2016, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[3] M. Behr,et al. Latent Mycobacterium tuberculosis Infection and Interferon-Gamma Release Assays. , 2016, Microbiology spectrum.
[4] Madhukar Pai,et al. Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? , 2016, European Respiratory Journal.
[5] Daniel E. Zak,et al. A prospective blood RNA signature for tuberculosis disease risk , 2016, The Lancet.
[6] F. Cobelens,et al. Feasibility and Operational Performance of Tuberculosis Detection by Loop-Mediated Isothermal Amplification Platform in Decentralized Settings: Results from a Multicenter Study , 2016, Journal of Clinical Microbiology.
[7] M. Pai,et al. Treatment as diagnosis and diagnosis as treatment: empirical management of presumptive tuberculosis in India. , 2016, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[8] K. Dheda,et al. Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial , 2016, The Lancet.
[9] G. Gore,et al. Impact of Molecular Diagnostics for Tuberculosis on Patient-Important Outcomes: A Systematic Review of Study Methodologies , 2016, PloS one.
[10] Purvesh Khatri,et al. Genome-wide expression for diagnosis of pulmonary tuberculosis: a multicohort analysis. , 2016, The Lancet. Respiratory medicine.
[11] M. Perkins,et al. Market assessment of tuberculosis diagnostics in China in 2012. , 2016, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[12] S. Lawn,et al. Detection of lipoarabinomannan (LAM) in urine is indicative of disseminated TB with renal involvement in patients living with HIV and advanced immunodeficiency: evidence and implications , 2016, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[13] M. Pai,et al. Xpert MTB/RIF for tuberculosis testing: access and price in highly privatised health markets. , 2016, The Lancet. Global health.
[14] Thomas R Rogers,et al. Rapid, comprehensive, and affordable mycobacterial diagnosis with whole-genome sequencing: a prospective study , 2016, The Lancet. Respiratory medicine.
[15] M. Perkins,et al. Market assessment of tuberculosis diagnostics in India in 2013. , 2016, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[16] M. Pai,et al. Use of standardised patients to assess quality of tuberculosis care: a pilot, cross-sectional study. , 2015, The Lancet. Infectious diseases.
[17] C. Karp,et al. Transformative tools for tackling tuberculosis , 2015, The Journal of experimental medicine.
[18] Phelim Bradley,et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study , 2015, The Lancet. Infectious diseases.
[19] M. Pai,et al. Use of chest radiography in the 22 highest tuberculosis burden countries , 2015, European Respiratory Journal.
[20] Christopher Dye,et al. Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. , 2015, The Lancet. Global health.
[21] N. Dendukuri,et al. Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in children: a systematic review and meta-analysis. , 2015, The Lancet. Respiratory medicine.
[22] M. Pai,et al. Potential market for novel tuberculosis diagnostics: worth the investment? , 2015, The Journal of infectious diseases.
[23] Marco Schito,et al. Defining the needs for next generation assays for tuberculosis. , 2015, The Journal of infectious diseases.
[24] M. Perkins,et al. Target product profile of a molecular drug-susceptibility test for use in microscopy centers. , 2015, The Journal of infectious diseases.
[25] M. Perkins,et al. Integration of published information into a resistance-associated mutation database for Mycobacterium tuberculosis. , 2015, The Journal of infectious diseases.
[26] M. Pai. Innovations in Tuberculosis Diagnostics: Progress and Translational Challenges , 2015, EBioMedicine.
[27] Suhail Ahmad,et al. Discordance between Xpert MTB/RIF Assay and Bactec MGIT 960 Culture System for Detection of Rifampin-Resistant Mycobacterium tuberculosis Isolates in a Country with a Low Tuberculosis (TB) Incidence , 2015, Journal of Clinical Microbiology.
[28] Market assessment of tuberculosis diagnostics in South Africa, 2012-2013. , 2015, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[29] S. Lawn,et al. Diagnostic accuracy of the Xpert MTB/RIF assay for extrapulmonary and pulmonary tuberculosis when testing non-respiratory samples: a systematic review , 2014, BMC Infectious Diseases.
[30] K. Steingart,et al. The diagnostic accuracy of the GenoType® Mtbdrsl assay for the detection of resistance to second-line anti-tuberculosis drugs , 2014, The Cochrane database of systematic reviews.
[31] N. Beyers,et al. A Comparison of Multidrug-Resistant Tuberculosis Treatment Commencement Times in MDRTBPlus Line Probe Assay and Xpert® MTB/RIF-Based Algorithms in a Routine Operational Setting in Cape Town , 2014, PloS one.
[32] L. Coin,et al. Diagnosis of childhood tuberculosis and host RNA expression in Africa. , 2014, The New England journal of medicine.
[33] N. Dendukuri,et al. Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis , 2014, European Respiratory Journal.
[34] M. Pai,et al. Tuberculosis diagnostics: which target product profiles should be prioritised? , 2014, European Respiratory Journal.
[35] C. Sreeramareddy,et al. Delays in diagnosis and treatment of pulmonary tuberculosis in India: a systematic review. , 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[36] Grant Theron,et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial , 2014, The Lancet.
[37] Hiroyuki Yamada,et al. Comparative evaluation of three immunochromatographic identification tests for culture confirmation of Mycobacterium tuberculosis complex , 2014, BMC Infectious Diseases.
[38] N. Dendukuri,et al. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults , 2014, The Cochrane database of systematic reviews.
[39] A. Diacon,et al. Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. , 2013, The Lancet. Respiratory medicine.
[40] L. Rigouts,et al. Rifampin Resistance Missed in Automated Liquid Culture System for Mycobacterium tuberculosis Isolates with Specific rpoB Mutations , 2013, Journal of Clinical Microbiology.
[41] Dominique N. Price,et al. Association of lipoarabinomannan with high density lipoprotein in blood: implications for diagnostics. , 2013, Tuberculosis.
[42] M. Perkins,et al. Tuberculosis 2013 : 4 Alignment of new tuberculosis drug regimens and drug susceptibility testing : a framework for action , 2013 .
[43] P. V. van Helden,et al. Implementation of genotype MTBDRplus reduces time to multidrug-resistant tuberculosis therapy initiation in South Africa. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[44] P. V. van Helden,et al. The Diagnostic Performance of the GenoType MTBDRplus Version 2 Line Probe Assay Is Equivalent to That of the Xpert MTB/RIF Assay , 2012, Journal of Clinical Microbiology.
[45] Graham Bothamley,et al. Point-of-care breath test for biomarkers of active pulmonary tuberculosis. , 2012, Tuberculosis.
[46] S. Lawn,et al. Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review , 2012, BMC Infectious Diseases.
[47] S. Lawn,et al. Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. , 2011, Future microbiology.
[48] Virginia Pascual,et al. An Interferon-Inducible Neutrophil-Driven Blood Transcriptional Signature in Human Tuberculosis , 2010, Nature.
[49] S. Swaminathan,et al. Pediatric tuberculosis: global overview and challenges. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[50] Irene Ayakaka,et al. Rapid Detection of Mycobacterium tuberculosis and Rifampin Resistance by Use of On-Demand, Near-Patient Technology , 2009, Journal of Clinical Microbiology.
[51] M. Pai,et al. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis , 2008, European Respiratory Journal.
[52] M. Perkins,et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. , 2006, The Lancet. Infectious diseases.
[53] M. Perkins,et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. , 2006, The Lancet. Infectious diseases.